Objectives: In this study, we aimed to investigate the bone turnover marker levels according to bisphosphonate usage and radiotherapy (RT) in cancer patients with metastases in osteolytic pattern.
Patients And Methods: A total of 52 patients (13 males, 39 females; median age: 52 years; range, 37 to 78 years) treated with RT for osteolytic bone metastases between April 2005 and April 2006 were retrospectively analyzed. Bone-specific alkaline phosphatase (BAP), amino-terminal cross-linked telopeptide of type I collagen (NTX-I), amino-terminal propeptide of type I procollagen (PINP), osteocalcin (OC), deoxypyridinoline (DPD), pyridinoline (PYD), alkaline phosphatase (ALP), creatinine, calcium (Ca), phosphate (P), magnesium (Mg), and 24-h urine Ca levels were measured in blood and urine before the initiation of RT, six weeks and six months after RT.
Results: A decrease in BAP, PINP, and creatinine levels was observed after RT (Week 6 p=0.006, Month 6 p=0.008). Sixteen patients who already used bisphosphonate before RT were excluded from statistical calculation. The remaining 36 patients who were treated with bisphosphonate after the first blood test were evaluated separately. In this group of patients, BAP, PINP, NTX, creatinine, and Ca levels significantly increased at six weeks after RT. The PINP and creatinine values significantly decreased at six months after RT. The variation between two different RT arms was assessed with repeated measures variance analysis. There was a statistically significant difference for NTX, OC, and creatinine levels between the first and second measurements.
Conclusion: Radiotherapy is an effective method in the treatment of osteolytic bone metastases. Bone turnover markers can provide an objective evaluation on RT response and parallel to imaging modalities criteria for evaluation. Bisphosphonates may alter the levels of these indicators. However, in this study, there were no statistically significant differences between the levels of markers for two different RT schedules.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650665 | PMC |
| http://dx.doi.org/10.52312/jdrs.2021.76037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolomic and transcriptomic remodeling of bone marrow myeloid cells in response to maternal obesity.
Am J Physiol Endocrinol Metab
January 2025
Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 97239.
Maternal obesity puts the offspring at high risk of developing obesity and cardio-metabolic diseases in adulthood. Here, we utilized a mouse model of maternal high-fat diet (HFD)-induced obesity that recapitulates metabolic perturbations seen in humans. We show increased adiposity in the offspring of HFD-fed mothers (Off-HFD) when compared to the offspring regular diet-fed mothers (Off-RD).
View Article and Find Full Text PDFBone Turnover Markers Predict Changes in Bone Mineral Density in Men Treated with Abaloparatide: Results from ATOM.
J Bone Miner Res
January 2025
Radius Health Inc, Boston, MA, United States.
Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-month bone mineral density (BMD) increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men. In this analysis, the correlation between changes from baseline in fasting intact serum procollagen type I N propeptide (PINP) and serum carboxy-terminal cross-linking telopeptide of type I collagen (CTX) at 1, 3, 6, and 12 months and percent increase from baseline in BMD at 12 months in men from the randomized phase 3 ATOM study (NCT03512262) were evaluated using Pearson's correlation coefficients. The uncoupling index (UI), a measure of the balance between markers of bone formation (PINP) and bone resorption (CTX), with positive UI favoring bone formation, was calculated.
View Article and Find Full Text PDFImpact of Platelet-rich Plasma and Platelet-rich Fibrin in Mandibular Third Molar Extraction: A Systematic Review.
J Contemp Dent Pract
September 2024
Department of Periodontology, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, India.
Aim: This study aims to evaluate the impact of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on pain, swelling, trismus, soft tissue healing and bone regeneration following mandibular third molar extraction.
Material And Methods: A systematic review was conducted from a period of January 2014 to June 2024 using PRISMA guidelines. The search strategy included databases such as Scopus, PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials, using key terms related to "PRF", "PRP", oral surgery, and third molars.
Increasing Bone Regeneration in Maxillary Sinus Augmentation Using Platelet-rich Fibrin: An Interventional Pre-Post Study.
J Contemp Dent Pract
September 2024
Department of Pediatrics Dentistry and Orthodontics, Faculty Odonto-Stomatology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam.
Aim: This study aimed to evaluate the impact of a combination of immediate implant placement with maxillary sinus augmentation (MSA) solely using platelet-rich fibrin (PRF) on guided bone regeneration.
Materials And Methods: An interventional before-after (pre-post) study design was used with 30 dental patients (≥18 years of age; 14 males and 16 females) with initial bone heights ranging between 4 and 6 mm. Following the general check-up and the creation of a study model, the planned implant location demonstrated an external right maxilla diameter of more than 5 mm, thereby validating the cone-beam computed tomography (CBCT) radiograph.
Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation.
Curr Drug Targets
January 2025
Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL33458, United States.
Diseases affecting bone encompass a spectrum of disorders, from prevalent conditions such as osteoporosis and Paget's disease, collectively impacting millions, to rare genetic disorders including Fibrodysplasia Ossificans Progressiva (FOP). While several classes of drugs, such as bisphosphonates, synthetic hormones, and antibodies, are utilized in the treatment of bone diseases, their efficacy is often curtailed by issues of tolerability and high incidence of adverse effects. Developing therapeutic agents for bone diseases is hampered by the fact that numerous pathways regulating bone metabolism also perform pivotal functions in other organ systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!